Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-4 of 4
Keywords: Decitabine
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Abhishek Maiti, Miguel J. Franquiz, Farhad Ravandi, Jorge E. Cortes, Elias J. Jabbour, Koji Sasaki, Kayleigh Marx, Naval G. Daver, Tapan M. Kadia, Marina Y. Konopleva, Lucia Masarova, Gautam Borthakur, Courtney D. DiNardo, Kiran Naqvi, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short
Journal:
Acta Haematologica
Acta Haematol (2020) 143 (6): 567–573.
Published Online: 09 February 2021
... of prior therapy cycles was 5 (range 2–8). Nine patients received decitabine-based, and 7 received intensive chemotherapy-based regimens. Ten patients (63%) received ponatinib. The overall response rate (ORR) in 15 evaluable patients was 60% (1 complete remission [CR], 6 CR with incomplete hematologic...
Journal Articles
Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms
Selena Zhou, Douglas Tremblay, Ronald Hoffman, Marina Kremyanskaya, Vesna Najfeld, Lihua Li, Erin Moshier, John Mascarenhas
Journal:
Acta Haematologica
Acta Haematol (2021) 144 (1): 48–57.
Published Online: 11 March 2020
...Selena Zhou; Douglas Tremblay; Ronald Hoffman; Marina Kremyanskaya; Vesna Najfeld; Lihua Li; Erin Moshier; John Mascarenhas Treatment options are limited for patients with advanced forms of myeloproliferative neoplasms (MPN) including blast-phase disease (MPN-BP). Decitabine has frequently been...
Journal Articles
Hongmin Li, Liru Wang, Yue Wu, Li Su, Hong Zhao, Yongqing Zhang, Zhao Wang, Dayong Huang, Zhongxia Huang, Xiaoxiong Wu, Xiaohong Li, Fang Ye, Fan Yu, Hui Liu, Jing-Wen Wang, Jia Cong, Wanjun Sun, Hui-Ren Chen, Jingbo Wang, Bing Han
Journal:
Acta Haematologica
Acta Haematol (2017) 138 (3): 168–174.
Published Online: 19 October 2017
...Hongmin Li; Liru Wang; Yue Wu; Li Su; Hong Zhao; Yongqing Zhang; Zhao Wang; Dayong Huang; Zhongxia Huang; Xiaoxiong Wu; Xiaohong Li; Fang Ye; Fan Yu; Hui Liu; Jing-Wen Wang; Jia Cong; Wanjun Sun; Hui-Ren Chen; Jingbo Wang; Bing Han Nowadays, the regular recommended dose of decitabine...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2017) 137 (4): 195–200.
Published Online: 27 April 2017
...Hongyu Zhao; Li Xu; Yongjian Yang; Jianhua Shao; Ping Chen; Xuebin Dong; Linping Gu; Daqi Li Aims: To investigate the safety and efficacy of the triple therapy of decitabine, idarubicin, and cytarabine in the treatment of refractory or recurrent acute myeloid leukemia (R/R AML). Methods: We...
